UBS Group’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-6,557
| Closed | -$25.4K | – | 10643 |
|
|
2024
Q3 | $25.4K | Buy |
+6,557
| New | +$18.2K | ﹤0.01% | 7233 |
|
|
2024
Q2 | – | Sell |
-3,733
| Closed | -$10.5K | – | 10288 |
|
|
2024
Q1 | $10.5K | Buy |
3,733
+3,659
| +4,945% | +$10.8K | ﹤0.01% | 7225 |
|
|
2023
Q4 | $235 | Buy |
+74
| New | +$252 | ﹤0.01% | 8787 |
|
|
2023
Q1 | – | Sell |
-2,033
| Closed | -$7.34K | – | 10647 |
|
|
2022
Q4 | $7.34K | Buy |
2,033
+1,291
| +174% | +$8.44K | ﹤0.01% | 8907 |
|
|
2022
Q3 | $6K | Sell |
742
-1,194
| -62% | -$9.92K | ﹤0.01% | 9093 |
|
|
2022
Q2 | $15K | Sell |
1,936
-186
| -9% | -$1.49K | ﹤0.01% | 7323 |
|
|
2022
Q1 | $20K | Sell |
2,122
-3,472
| -62% | -$31K | ﹤0.01% | 7465 |
|
|
2021
Q4 | $39K | Buy |
5,594
+5,121
| +1,083% | +$43K | ﹤0.01% | 7159 |
|
|
2021
Q3 | $4K | Buy |
473
+362
| +326% | +$3.4K | ﹤0.01% | 8703 |
|
|
2021
Q2 | $1K | Sell |
111
-1,226
| -92% | -$13.6K | ﹤0.01% | 9209 |
|
|
2021
Q1 | $15K | Buy |
1,337
+395
| +42% | +$6.64K | ﹤0.01% | 7636 |
|
|
2020
Q4 | $34K | Sell |
942
-662
| -41% | -$11.4K | ﹤0.01% | 6540 |
|
|
2020
Q3 | $23K | Buy |
1,604
+1,493
| +1,345% | +$22.3K | ﹤0.01% | 6215 |
|
|
2020
Q2 | $2K | Sell |
111
-1,165
| -91% | -$13.9K | ﹤0.01% | 7670 |
|
|
2020
Q1 | $11K | Buy |
1,276
+673
| +112% | +$9.41K | ﹤0.01% | 6888 |
|
|
2019
Q4 | $14K | Sell |
603
-304
| -34% | -$4.34K | ﹤0.01% | 7109 |
|
|
2019
Q3 | $13K | Buy |
907
+271
| +43% | +$3.98K | ﹤0.01% | 7012 |
|
|
2019
Q2 | $8K | Sell |
636
-157
| -20% | -$2.37K | ﹤0.01% | 7210 |
|
|
2019
Q1 | $14K | Sell |
793
-1,248
| -61% | -$18.6K | ﹤0.01% | 6604 |
|
|
2018
Q4 | $28K | Buy |
2,041
+1,550
| +316% | +$27.3K | ﹤0.01% | 6542 |
|
|
2018
Q3 | $11K | Sell |
491
-524
| -52% | -$15.9K | ﹤0.01% | 7126 |
|
|
2018
Q2 | $44K | Buy |
1,015
+372
| +58% | +$17K | ﹤0.01% | 6084 |
|
|
2018
Q1 | $42K | Buy |
643
+189
| +42% | +$13.4K | ﹤0.01% | 5855 |
|
|
2017
Q4 | $33K | Buy |
454
+95
| +26% | +$7.86K | ﹤0.01% | 6170 |
|
|
2017
Q3 | $33K | Sell |
359
-65
| -15% | -$4.99K | ﹤0.01% | 6100 |
|
|
2017
Q2 | $28K | Buy |
424
+202
| +91% | +$25K | ﹤0.01% | 6065 |
|
|
2017
Q1 | $48K | Sell |
222
-628
| -74% | -$89.7K | ﹤0.01% | 5551 |
|
|
2016
Q4 | $79K | Sell |
850
-115
| -12% | -$13K | ﹤0.01% | 5462 |
|
|
2016
Q3 | $131K | Sell |
965
-205
| -18% | -$20.4K | ﹤0.01% | 4829 |
|
|
2016
Q2 | $119K | Buy |
1,170
+512
| +78% | +$63.5K | ﹤0.01% | 4910 |
|
|
2016
Q1 | $107K | Sell |
658
-7,782
| -92% | -$1.58M | ﹤0.01% | 4930 |
|
|
2015
Q4 | $2.76M | Buy |
8,440
+6,474
| +329% | +$2.11M | ﹤0.01% | 2502 |
|
|
2015
Q3 | $634K | Buy |
1,966
+575
| +41% | +$253K | ﹤0.01% | 3708 |
|
|
2015
Q2 | $554K | Buy |
1,391
+235
| +20% | +$99.9K | ﹤0.01% | 4033 |
|
|
2015
Q1 | $569K | Buy |
1,156
+406
| +54% | +$157K | ﹤0.01% | 4041 |
|
|
2014
Q4 | $268K | Buy |
+750
| New | +$223K | ﹤0.01% | 4760 |
|
UBS Group's LUMO Position: Q4 2024 in Review
UBS Group sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 6,557 shares — an estimated $25.4K sold.
UBS Group first reported a position in LUMO in Q4 2014 and held it in 36 quarters. The position peaked at $2.76M in Q4 2015. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.
- UBS Group reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- UBS Group sold 6,557 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $25.4K.
- UBS Group first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2014 and held it in 36 quarters.
- UBS Group's Lumos Pharma, Inc. Common Stock position peaked at $2.76M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.
Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.